BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers—General | NSD

Last Closing Price

USD 282.35

Change

+0.31 (+0.11)%

Market Cap

USD 44.65B

Volume

0.86M

Average Target Price

USD 298.13 (+5.59%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMGN Amgen Inc

+1.27 (+0.51%)

USD144.68B 20.25 13.34
SNY Sanofi

-0.50 (-0.98%)

USD127.56B 9.80 7.72
GILD Gilead Sciences, Inc

-0.75 (-1.19%)

USD78.80B 18.91 46.27
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
HZNP Horizon Therapeutics Public Li..

-1.51 (-1.90%)

USD17.56B 28.75 52.14
GRFS Grifols, S.A

-0.09 (-0.53%)

USD16.70B 17.62 17.32
GWPH GW Pharmaceuticals plc

-1.68 (-1.69%)

USD3.20B 91.14 84.16

ETFs Containing BIIB

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+0.20 (+0.12%)

USD0.49B
DQML Reality Shares Fundstrat .. 0.00 % 0.69 %

N/A

USD2.62M
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.31%)

N/A
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.06 (+0.57%)

USD3.93M
VVAL:LSE Vanguard Global Value Fac.. 0.00 % 0.00 %

-0.24 (-1.10%)

USD0.24B
OPEN:LSE iShares Thomson Reuters I.. 0.00 % 0.25 %

-0.03 (-0.61%)

USD4.74M
MOAT:LSE VanEck Vectors Morningsta.. 0.00 % 0.49 %

-0.39 (-0.98%)

USD0.22B
IFSW:LSE iShares Edge MSCI World M.. 0.00 % 0.50 %

-0.01 (-0.10%)

N/A
IFSU:LSE iShares IV Public Limited.. 0.00 % 0.35 %

-0.01 (-0.08%)

USD0.08B
FEXU:LSE First Trust US Large Cap .. 0.00 % 0.75 %

+0.38 (+0.76%)

USD0.13B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.05 (+0.84%)

USD0.26B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.04 (+0.86%)

USD0.26B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.05 (+0.87%)

USD0.07B
AMOM QRAFT AI-Enhanced U.S. La.. 0.00 % 0.75 %

+0.22 (+0.62%)

USD2.98M
ZIG The Acquirers Fund ETF 0.00 % 0.94 %

N/A

USD0.02B
VALQ American Century STOXX U... 0.00 % 0.29 %

-0.08 (-0.21%)

USD0.13B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.21 (+0.30%)

USD0.21B
FFIU Fieldstone UVA Unconstrai.. 0.00 % 0.51 %

-0.04 (-0.13%)

USD0.06B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.37 %

-0.23 (-0.85%)

USD0.05B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.63 (+1.12%)

USD0.26B
ONEO SPDR Russell 1000 Momentu.. 0.00 % 0.20 %

-0.03 (-0.05%)

USD0.31B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

-0.02 (-0.08%)

USD0.04B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

+0.13 (+0.10%)

USD9.52B
FXH First Trust Health Care A.. 0.00 % 0.62 %

+0.38 (+0.41%)

USD1.30B
FTA First Trust Large Cap Val.. 0.00 % 0.60 %

-0.48 (-1.03%)

USD0.60B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+0.29 (+0.19%)

USD2.15B
FAB First Trust Multi Cap Val.. 0.00 % 0.71 %

-0.54 (-1.15%)

USD0.05B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.08 (-0.25%)

USD0.01B
FTGU:XETRA First Trust US Large Cap .. 0.00 % 0.00 %

-0.45 (-1.05%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.85% 43% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.85% 43% F 51% F
Trailing 12 Months  
Capital Gain 24.27% 71% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.27% 71% C- 71% C-
Trailing 5 Years  
Capital Gain -1.72% 29% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.72% 29% F 40% F
Average Annual (5 Year Horizon)  
Capital Gain 2.49% N/A N/A 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.49% N/A N/A 40% F
Risk Return Profile  
Volatility (Standard Deviation) 16.67% N/A N/A 77% C+
Risk Adjusted Return 14.92% N/A N/A 42% F
Market Capitalization 44.65B 57% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.93 100% A+ 76% C
Price/Book Ratio 3.78 71% C- 33% F
Price / Cash Flow Ratio 6.31 86% B 40% F
EV/EBITDA 5.70 100% A+ 80% B-
Management Effectiveness  
Return on Equity 49.38% 86% B 98% A+
Return on Invested Capital 30.75% 100% A+ 95% A
Return on Assets 18.31% 100% A+ 99% A+
Debt to Equity Ratio 33.42% 86% B 53% F
Technical Ratios  
Short Ratio 3.23 43% F 50% F
Short Percent 2.34% 25% F 59% F
Beta 0.52 71% C- 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:

There is nothing we particularly dislike